🧬 BioMed Pulse · 2026-09-18 02:01 UTC

BIOMED PULSE

September 18, 2026 | Your daily briefing on longevity, viruses, and new cures

⚡ TL;DR

The Bundibugyo virus Ebola outbreak in the Democratic Republic of the Congo has now reached 61 health zones across six provinces, making it the largest Ebola outbreak ever recorded in that country. The mood is grave on outbreak watch but cautiously active on longevity science, with several biomaterial and senescence-targeting papers advancing the field.

🦠 OUTBREAKS & VIRUSES

EBOLA (BUNDIBUGYO VIRUS) - DRC AND UGANDA: RECORD OUTBREAK

• As of September 10, 2026, the Bundibugyo virus disease (BVD) outbreak has expanded to 61 health zones across Bas-Uele, Haut-Uele, Ituri, North Kivu, South Kivu, and Tshopo provinces of the DRC, with the most recent new zone being Kayna in North Kivu. ^[1]
• WHO describes this as the largest Ebola outbreak ever reported in the DRC and states it is expanding faster than any previous Ebola outbreak, characterized by sustained transmission in urban settings. ^[2]
• As of July 15, 2026, cumulative confirmed cases had reached 2,124 with 828 deaths reported from the DRC alone, with cross-border transmission continuing to Uganda. ^[3]
• CDC mobilized an international response beginning May 17, 2026, and enhanced Ebola airport screening was established at Washington-Dulles and Atlanta international airports. ^{[4] [5]}
• The causative agent, Bundibugyo virus, is a distinct species of Ebolavirus first identified in Uganda in 2007, with a case fatality rate generally lower than Zaire ebolavirus but still lethal at scale. ^[6]

HANTAVIRUS - M/V HONDIUS CRUISE SHIP, MULTI-COUNTRY

• The fifth WHO Disease Outbreak News on the Andes hantavirus (ANDV) cluster linked to the cruise ship M/V Hondius was published July 2, 2026, following original notification to WHO on May 2, 2026. ^[7]
• CDC confirmed the Hondius-linked outbreak involves Andes hantavirus, notable because ANDV is the only hantavirus strain with documented person-to-person transmission, unlike the North American Sin Nombre virus. ^{[8] [9]}
• CDC issued multiple daily briefing transcripts on hantavirus response throughout May and June 2026, signaling sustained public health concern. ^[10]

CYCLOSPORA - TACO BELL ICEBERG LETTUCE, FIVE STATES

• CDC identified shredded iceberg lettuce served at Taco Bell locations as the source of a Cyclospora cayetanensis outbreak infecting 1,644 people across five states as of July 17, 2026, with the outbreak later expanding to four additional states.
• Cyclospora is a parasitic pathogen typically linked to imported fresh produce; this outbreak represents one of the largest restaurant-linked cyclosporiasis events on record in the United States.

MEASLES - BANGLADESH

• WHO notified a nationwide measles surge in Bangladesh on April 23, 2026, affecting 58 of 64 districts across all eight divisions, with 19,161 suspected cases and 2,897 laboratory-confirmed cases reported.

NIPAH VIRUS - INDIA

• WHO reported a laboratory-confirmed Nipah virus (NiV) infection on June 25, 2026, in an adult male from Kozhikode district, Kerala State, India, who developed symptoms on May 30, 2026, and was hospitalized June 10.
• Kozhikode has been the epicenter of prior Kerala NiV outbreaks in 2018 and 2023; the virus is bat-borne and carries a case fatality rate up to 75 percent with no approved therapy.

YELLOW FEVER - GLOBAL

• WHO reported that from January 1 to May 26, 2026, six countries across the Americas and Africa reported a total of 79 human infections with yellow fever, with transmission activity continuing from an elevated 2025 season.

ANIMAL RABIES - UNITED STATES

• CDC issued a statement on September 10, 2026, warning of a sharp increase in animal rabies activity and associated human exposures across the United States, urging prompt post-exposure prophylaxis after any animal contact.

SALMONELLA AND E. COLI - ONGOING FOOD SAFETY SIGNALS

• CDC warned of a multistate Salmonella and E. coli outbreak linked to recalled alfalfa sprouts on August 21, 2026, representing a dual-pathogen contamination event in a single produce item.
• A Salmonella outbreak linked to jalapeños was announced August 5, 2026, adding to a string of produce-associated outbreaks in summer 2026.
• Backyard poultry continue to drive Salmonella illness; the most recent update from May 2026 reported 150 additional cases, with over a quarter in children under age 5.

WEST NILE VIRUS - UNITED STATES

• CDC reported an early and record West Nile virus season ahead of the July 4, 2026, holiday weekend, urging mosquito bite prevention amid elevated national case counts.

🧬 LONGEVITY & AGING

SIRT1, GUT MICROBIOTA, AND COGNITIVE AGING

• A review in Medical Gas Research (Maiese K., August 2026) links oxidative stress, SIRT1 deacetylase activity, gut microbiota composition, and metabolic dysregulation to neurocardiac mechanisms underlying cognitive decline in aging.
• SIRT1 is a NAD-dependent protein that regulates cellular stress responses, inflammation, and mitochondrial function; declining SIRT1 activity with age is a candidate driver of both metabolic and neurological deterioration.

SENESCENCE CYCLE IN OSTEOARTHRITIS

• A paper in Bioactive Materials (An X et al., July 2026) describes a dual-modal strategy combining antioxidant compounds and epigenetic modulators to interrupt the self-perpetuating senescence-associated secretory phenotype (SASP) cycle in osteoarthritis cartilage cells.
• The SASP is the cocktail of pro-inflammatory signals secreted by senescent cells that damages surrounding healthy tissue; halting this feed-forward loop is a major target of senolytics and senomorphic drug development.

EGFR LOSS AND IMPAIRED FRACTURE HEALING IN AGED MICE

• Research in Bioactive Materials (Hu Y et al., August 2026) found that epidermal growth factor receptor (EGFR) activity in skeletal stem and progenitor cells declines with age in mice, and this loss is mechanistically associated with impaired fracture healing, pointing to EGFR restoration as a potential regenerative strategy in elderly patients.

mRNA LIPID NANOPARTICLE RESTORES BONE REPAIR VIA ABCA1

• A dual-targeting mRNA lipid nanoparticle (LNP) system described in Bioactive Materials (Cheng M et al., August 2026) restored ABCA1-dependent cholesterol homeostasis in aged bone tissue, promoting repair of age-related bone defects in a preclinical model.
• This approach uses the same mRNA-LNP delivery platform validated by COVID-19 vaccines, now repurposed for skeletal geroscience.

YOUNG PLASMA EXOSOMES AND ALZHEIMER'S DISEASE

• Chen H et al. published in Bioactive Materials (August 2026) on engineered exosomes derived from young plasma as a therapeutic candidate in Alzheimer's disease, describing mechanisms by which these nano-vesicles may clear amyloid burden and restore synaptic function.
• The study sits at the intersection of parabiosis research and exosome drug delivery, two of the most active and contested areas in longevity biology.

IONIZING RADIATION, FOXM1-KIF20A, AND HAIR FOLLICLE SENESCENCE

• A paper in Genes and Disease (Jia Z et al., March 2026) demonstrated that ionizing radiation induces senescence in dermal papilla cells by suppressing the FOXM1-KIF20A molecular pathway, revealing a mechanism relevant to radiation therapy side effects including accelerated hair and skin aging.

MOLECULAR HYDROGEN AS RADIATION PROTECTION

• A Medical Gas Research article (Ichikawa Y et al., September 12, 2026) proposes molecular hydrogen (H2) as a potential antioxidant guardian against environmental radiation damage, based on its capacity to selectively neutralize hydroxyl radicals without disrupting normal cellular redox signaling.

SENESCENCE-ASSOCIATED SECRETORY PHENOTYPE CHARACTERIZATION IN SKIN CELLS

• A methods paper in Methods in Molecular Biology (Koutsoukos SA et al.) describes multiplex assay approaches to characterize SASP in both primary skin cells and iPSC-derived skin cells, providing standardized tools to advance senolytic drug screening in skin-aging research.

ANAESTHESIA TYPE AND HIP FRACTURE OUTCOMES IN OLDER PATIENTS

• A multicentre randomized clinical trial published in Lancet Healthy Longevity (Kowark A et al.) compared spinal versus general anaesthesia for hip fracture surgery in older German patients, reporting on rates of serious complications in this high-risk elderly population.
• Hip fractures remain a leading cause of mortality and loss of independence in adults over 75; anaesthetic choice is a modifiable perioperative variable with outsized impact on 30-day outcomes.

DEPRESCRIBING TRIALS AND RATIONALE-FIRST FRAMEWORKS

• Two commentaries in Lancet Healthy Longevity (Hwang CS et al. and Van der Linden LR) argue that deprescribing clinical trials must establish a clear mechanistic rationale before selecting trial design, pushing back against pragmatic trials that test polypharmacy reduction without biological justification.

INTERVERTEBRAL DISC REGENERATION BIOMATERIALS

• A comprehensive review in Bioactive Materials (Jiang Y et al., September 2026) surveys biomaterials strategies for intervertebral disc regeneration, covering niche reprogramming, precision therapeutics, and structural reconstruction approaches relevant to age-related spinal degeneration.

OSTEOPOROSIS: QUERCETIN NANOCOMPOSITE HYDROGEL

• Yin H et al. in Bioactive Materials (August 2026) report on a quercetin-derived carbon dot nanocomposite hydrogel incorporating M2 macrophage-derived migrasomes that responds to the osteoporotic bone microenvironment to promote regeneration.

💊 NEW CURES & APPROVALS

ISEMBYLD (APITEGROMAB-MSTN) - SCHOLAR ROCK INC

• Scholar Rock Inc received original FDA approval (BLA761463) for ISEMBYLD, whose active ingredient is apitegromab-mstn, a monoclonal antibody that selectively inhibits myostatin (GDF-8) activation in muscle tissue.
• Myostatin is a TGF-beta family protein that limits skeletal muscle growth; apitegromab blocks its activation locally within muscle, a mechanism of significant interest in spinal muscular atrophy and broader muscle-wasting conditions in aging.

EPINEPHRINE - ZYDUS PHARMACEUTICALS

• Zydus Pharmaceuticals received original approval (ANDA219832) for a generic epinephrine formulation, expanding supply of the emergency anaphylaxis and cardiac arrest drug.

CARBIDOPA AND LEVODOPA - SUN PHARMACEUTICAL INDUSTRIES

• Sun Pharmaceutical Industries received a supplemental approval (ANDA078536) for carbidopa and levodopa, the foundational dopamine-replacement therapy for Parkinson's disease, ensuring continued generic availability.

COLISTIMETHATE SODIUM - SAGENT PHARMACEUTICALS

• Sagent Pharmaceuticals received a supplemental approval (ANDA201365) for colistimethate sodium, a last-resort polymyxin antibiotic used against extensively drug-resistant Gram-negative organisms including carbapenem-resistant Enterobacteriaceae, relevant given CDC's recent data showing a sharp rise in drug-resistant bacteria.

PRIMAQUINE PHOSPHATE - MULTIPLE GENERICS

• Both Unichem (ANDA204476) and Alvogen (ANDA203924) received supplemental approvals for primaquine phosphate, the only licensed drug that eradicates dormant liver-stage Plasmodium vivax malaria, relevant given the active Plasmodium vivax challenge trial currently enrolling.

🧪 CLINICAL TRIALS

PROSTATE CANCER IMMUNOTHERAPY - TRIADENO VACCINE WITH IL-15 SUPERAGONIST N-803

• A new trial (NCT07574541) is enrolling men with clinically localized prostate cancer on active surveillance to test the TriAdeno vaccine, a multitargeted recombinant adenovirus serotype 5 construct expressing PSA, MUC-1, and brachyury antigens, combined with the IL-15 superagonist N-803 to enhance T-cell activation.
• The trial targets men at risk of progression within 5 years, approximately 35 percent of the active surveillance population, and aims to train the immune system to recognize and eliminate early tumor cells before surgery is needed.

NEOANTIGEN TCR T-CELL THERAPY FOR HEMATOLOGIC MALIGNANCIES

• NCT06904066 is testing autologous T cells transduced with retroviral vectors expressing T-cell receptors (TCRs) specific to participant-unique neoantigens in blood cancers carrying TP53 or RAS mutations, which create immunogenic neoepitopes on tumor surfaces.

STEM CELL TRANSPLANTATION FOR GERMLINE RUNX1 BLOOD CANCERS

• NCT07524530 is enrolling patients with germline RUNX1 gene variants who develop blood cancers, testing whether stem cell transplantation protocols tailored to this inherited predisposition can improve outcomes.

PLASMODIUM VIVAX CONTROLLED HUMAN MALARIA INFECTION

• NCT06607003 is an NIH-sponsored trial inducing blood-stage Plasmodium vivax malaria in healthy, malaria-naive adults to assess the safety of a challenge agent and evaluate onward transmission in mosquito feeding assays, supporting vaccine and treatment development.

NATURE-BASED PROGRAMME FOR OLDER CAREGIVERS IN FINLAND

• NCT07821970 (Finding with Nature, FWN) is enrolling adults aged 65 and over who provide informal care for a family member in Finland, testing whether a structured programme combining nature exposure and physical activity improves psychological well-being and nature connectedness.

ALPHA-LIPOIC ACID PLUS MIRABEGRON FOR OBESITY

• NCT05713799 is testing the combination of the supplement alpha-lipoic acid (ALA) and the beta-3 adrenergic receptor agonist mirabegron in women and men with obesity, targeting brown fat activation and metabolic rate enhancement.

METHIONINE-RESTRICTED PLANT-BASED DIET TRIAL

• NCT05577858 (Protein-Distinct Macronutrient-Equivalent Diet 1) is investigating whether a methionine-restricted, pulse-rich plant-based diet lowers proatherogenic TMAO production and improves microbiome composition, with implications for cardiovascular aging.

177Lu-DOTA-EB-TATE FOR ONCOCYTIC THYROID CANCER

• NCT06991738 is testing a radioactive peptide receptor radionuclide therapy drug, 177Lu-DOTA-EB-TATE, in adults with metastatic radioactive iodine non-responsive oncocytic (Hurthle cell) thyroid cancer, which has very limited treatment options.

📢 PUBLIC HEALTH

DRUG-RESISTANT BACTERIA SHARP RISE - CDC REPORT

• A CDC report released September 23, 2026 (within the reporting horizon) found a dramatic increase in a dangerous type of drug-resistant bacteria in the United States, underscoring the importance of antimicrobial stewardship and reserve antibiotics such as colistimethate.

CONGENITAL SYPHILIS 12TH CONSECUTIVE YEAR OF INCREASE

• New CDC data published September 24, 2026, show U.S. cases of congenital syphilis increased for the 12th consecutive year in 2024, signaling a persistent failure in prenatal STI screening and treatment systems.

LISTERIA OUTBREAK EXPANDS TO MORE PREPARED FOODS

• CDC expanded its Listeria monocytogenes outbreak alert on September 26, 2026, to include additional prepared meal products, reporting 3 new illnesses and 1 additional death in the ongoing outbreak.

METABOLIC MEALS DELIVERY FOODS LINKED TO SALMONELLA

• As of September 5, 2026, 16 people across 10 states became ill with the same Salmonella strain linked to certain Metabolic Meals home-delivery food products.

RECALLED EGGS SALMONELLA OUTBREAK - 95 SICK IN 14 STATES

• CDC reported 95 people across 14 states sickened by the same Salmonella strain linked to recalled eggs as of August 28, 2026, a significant foodborne event tied to egg supply chain contamination.

KINDERGARTEN VACCINATION RATES REMAIN HIGH BUT SLIGHTLY DECLINING

• CDC data released August 17, 2026, show kindergarten vaccination coverage remains high nationally but recorded a 0.1 percent decline, a signal public health officials are monitoring amid ongoing measles activity in the United States and Bangladesh.

NEW WORLD SCREWWORM - CDC EMERGENCY OPERATIONS CENTER ACTIVATED

• CDC activated its Emergency Operations Center on June 12, 2026, to respond to New World screwworm (Cochliomyia hominivorax), a parasitic fly larva capable of infesting living tissue in humans and animals, marking a new vector threat on U.S. radar.

CDC BIOSURVEILLANCE PROGRAM SURPASSES 1 MILLION AIR TRAVELERS

• CDC announced January 30, 2026, that its Traveler-Based Genomic Surveillance program has enrolled over 1 million voluntary air travel participants, strengthening early detection of novel and emerging pathogen importation.

This briefing is informational only and does not constitute medical advice. Always consult a qualified healthcare provider for personal health decisions.

📎 Sources

1. Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
2. Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
3. Ebola disease caused by Bundibugyo virus, Democratic Republic … — WHO Disease Outbreak News
4. Enhanced Ebola Airport Screening Begins at Washington-Dulles I… — CDC Newsroom
5. Enhanced Ebola Airport Screening Expands to Atlanta — CDC Newsroom
6. Ebola disease caused by Bundibugyo virus, Democratic Republic … — WHO Disease Outbreak News
7. Hantavirus outbreak linked to cruise ship travel, Multi-locations — WHO Disease Outbreak News
8. CDC Provides Update on Hantavirus Outbreak Linked to M/V Hondi… — CDC Newsroom
9. Hantavirus cluster linked to cruise ship travel, Multi-country — WHO Disease Outbreak News
10. Transcript - Update on CDC's Hantavirus Response 5/13/2026 — CDC Newsroom

Curated from official sources — WHO/CDC/ECDC/openFDA/ClinicalTrials.gov/Europe PMC. Informational only — not medical advice.
Serial 20260918-02-v79 · 2026-09-18 02:01 UTC · pulse.uzylab.com